Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii plus vonoprazan–amoxicillin rescue therapy for refractory Helicobacter pylori infection
ChiCTR2300075382Phase 4Not yet recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Sep 2023
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of vonoprazan, amoxicillin and saccharomyces boulardii in Helicobacter pylori infection (2 arms), sponsored by Changzhou Second People's Hospital. Primary endpoint: Helicobacter pylori eradication rate. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillinsaccharomyces boulardii
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2300075382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075382.